Assessment
Questionnaire

Have a symptom?
See what questions
a doctor would ask.
 

Prevalence and Incidence of Metaphyseal chondrodysplasia Spahr type

Metaphyseal chondrodysplasia Spahr type: Rare Disease

Metaphyseal chondrodysplasia Spahr type is listed as a "rare disease" by the Office of Rare Diseases (ORD) of the National Institutes of Health (NIH). This means that Metaphyseal chondrodysplasia Spahr type, or a subtype of Metaphyseal chondrodysplasia Spahr type, affects less than 200,000 people in the US population.

Ophanet, who are a consortium of European partners, currently defines a condition rare when if affects 1 person per 2,000. They list Metaphyseal chondrodysplasia Spahr type as a "rare disease". More information about Metaphyseal chondrodysplasia Spahr type is available from Orphanet

About prevalence and incidence statistics:

The term 'prevalence' of Metaphyseal chondrodysplasia Spahr type usually refers to the estimated population of people who are managing Metaphyseal chondrodysplasia Spahr type at any given time. The term 'incidence' of Metaphyseal chondrodysplasia Spahr type refers to the annual diagnosis rate, or the number of new cases of Metaphyseal chondrodysplasia Spahr type diagnosed each year. Hence, these two statistics types can differ: a short-lived disease like flu can have high annual incidence but low prevalence, but a life-long disease like diabetes has a low annual incidence but high prevalence. For more information see about prevalence and incidence statistics.

 

By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.

Home | Symptoms | Diseases | Diagnosis | Videos | Tools | Forum | About Us | Terms of Use | Privacy Policy | Site Map | Advertise